World RNA Series

If you're feeling haunted by dsRNA, or spooked by developing, validating and transferring methods to demonstrate drug substance and product CQAs, then you're not alone.. 100 technical mRNA specialists will join us in February to hear the latest spook-tactular insights from the FDA, BioNTech, Moderna, Genentech, Sanofi, Sail Biomedicines and more - including progress on phase appropriate potency assays, analyzing novel cell-targeted delivery systems, and controlling dsRNA. Explore the fang-tastic agenda here: https://ter.li/pqzvf2 #mRNA #RNA #AnalyticalDevelopment #CMC #dsRNA

Merck and Moderna announced today the initiation of the Phase 3 trial evaluating V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT), in Combination with KEYTRUDA® (pembrolizumab) after neoadjuvant KEYTRUDA and chemotherapy in patients with certain types of non-small cell lung cancer (NSCLC).   Read more: https://lnkd.in/ezG4A7hR

An innovative clinical trial will open across the UK over the next two weeks in the hope of finding an effective vaccine against the highly contagious stomach bug, norovirus 🦠 Despite being one of the most common and infectious causes of gastroenteritis, there are not yet any licensed vaccines anywhere in the world. The trial hopes to change that, and will evaluate the efficacy and safety of the vaccine with up to 2,500 participants across 39 locations in the UK. We’re supporting the trial via our NIHR Research Delivery Network and the UK Vaccine Innovation Pathway. The trial is being run as part of a partnership between Moderna and the UK Health Security Agency on behalf of the UK Government. Read more about the trial ➡️ https://lnkd.in/emttAbYg

🌟 Join the Sharpest Minds in RNAi at the 6th RNAi-Based Therapeutics Summit! 🌟 Whether you're a seasoned RNAi pro or intrigued by its groundbreaking potential, here's why this is the event you can't miss: 🧠 28 Expert Speakers - Leading voices in the RNAi space, sharing brand-new data on targeting the placenta, kidney, muscle and adipose tissue 💬 2 Round Table Discussions - Dive deep into the hottest industry topics and and RNAi innovations for future opportunities with peers 💼 1 Investor Panel - Led by Eli Lilly and Company, Sunrise BioVentures, and Broadview Ventures Inc, discover what’s next in RNAi and the key factors investors are looking for Download the OFFICIAL BROCHURE: https://ter.li/4cb7jb This summit will bring together fellow RNAi peers and YOU could be part of it! Don’t miss your chance to network, learn, and lead the way in RNAi-based therapies. #RNAiTherapeutics #RNAiInnovation 

I'm excited to share that I'm presenting at the 4th mRNA Analytical Development & Quality Control Summit in Boston, February 25-27. If you're interested in mRNA characterization using cutting-edge methods, this is the place to be! See the full event guide here: https://ter.li/avgzuf

I’m so excited to share my thoughts on Unlocking Platform Approaches in Analytcal Development to Fast-Track Regulatory Submissions into the Clinic & Beyond!

Announcing the brand new 2025 agenda for the 4th mRNA Analytical Development & Quality Control Summit, returning to Boston bigger and better February 25-27, 2025! Download your copy here: https://ter.li/72rdrk For the very first time, this technically-focused forum will unite the analytical development, quality control, and assay development teams to address shared challenges and cross-department priorities to secure mRNA therapeutic and vaccine submissions in 2025 and beyond. 100+ mRNA specialists will delve into every aspect of drug substance and drug product method development, validation and transfer, and leave feeling empowered to deploy scalable and phase appropriate methods for CQAs, analyze LNP and cell-targeted delivery payloads, control dsRNA, and navigate the global mRNA therapeutic and vaccine regulatory seas. Be the first to see the agenda here: https://ter.li/72rdrk #mRNA #AnalyticalDevelopment #CMC #AssayDevelopment #QualityControl #WorldRNA

We are thrilled to welcome Professor Siow-Ming Lee, University College London, to the mRNA Based Therapeutics Summit Europe in January. During an unmissable session, Professor Siow-Ming Lee will explore the clinical trial experience and data from BNT116 – the UK’s first mRNA-based lung cancer vaccine trial. To learn more about this year’s event, access the event guide: https://ter.li/sl0v3j Don’t forget that this week is your last chance to save a huge €1,450 on your pass to the conference!

✨Alnylam Joins RNAi-Based Therapeutics!✨ Having developed 5 of the 6 RNAi medicines on the market, there is no doubt that Alnylam Pharmaceuticals is setting the example for siRNA therapeutics! Amongst Alnylam’s excitement, we’re thrilled to share that Muthiah (Mano) Manoharan, Senior Vice President, Innovation Chemistry & Alnylam Distinguished Scientist, is joining our expert speaker faculty to share a critical update with the community of 100+ RNAi leaders. Curious who else will be taking the stage? ✨ Download our exclusive brochure to get the full scoop: https://ter.li/fkqtkq P.S. Our largest savings yet (Save $1,100) runs out at midnight > https://ter.li/59rwca #RNAi #RNA #siRNA #Alnylam #SpeakerSpotlight

Ready to showcase your cutting-edge research to a global community of RNA-targeting experts? Join us this December in Boston at the 7th RNA-Targeted Drug Discovery & Development Summit for our exclusive scientific poster session! Exchange ideas, spark new conversations, and collaborate with fellow decision-makers advancing the RNA therapeutics field. Don’t miss this opportunity to be part of the innovation driving the future of drug discovery! Register your place today to submit an abstract for review and showcase your poster. Secure your spot by this Friday, October 18, to take advantage of early bird savings of up to $600! Hurry—this offer expires soon: https://ter.li/piey012 Want to know more? View the 2024 event guide here for full speaker and session information: https://ter.li/piey01 #RNADrugDiscovery #RNAResearch #RNAInnovation #RNACollaboration #RNAPartnerships